Symptomatic recurrence of *Clostridium difficile* infection (CDI) causes significant morbidity and can prove challenging to treat effectively \[[@CIS356C1]\]. It also inevitably increases the risk of *C. difficile* transmission. Reported recurrence rates vary from 5% to 50% and typically are around 20% \[[@CIS356C2]\].

In a meta-analysis, recurrence risk factors included older age, use of *C. difficile*--provocative antibiotics after CDI diagnosis, and concomitant receipt of antacids \[[@CIS356C3]\]. Other factors identified in individual studies include hospital-acquired disease \[[@CIS356C4]\]; comorbid conditions, including severe underlying illness \[[@CIS356C5]\] or poor quality of life scores \[[@CIS356C6]\]; and previous recurrent CDI \[[@CIS356C7]\]. However, most existing studies are relatively small and hospital based and predate the polymerase chain reaction (PCR) ribotype 027/sequence type 1 (ST1)/North American pulsed-field gel electrophoresis type 1 (NAP-1) epidemic \[[@CIS356C3]\], demonstrating a need for contemporaneous large-scale population-based studies. CDI most commonly recurs within a week \[[@CIS356C8]\] after treatment cessation but can recur up to 6--8 weeks later \[[@CIS356C9]\]. However, because most studies have followed patients for only 1--2 months \[[@CIS356C3]\], the pattern of longer-term recurrence is unclear. Up to 50% of apparent relapses have been identified as new infections with a different strain \[[@CIS356C10]--[@CIS356C13]\]; uncertainty about which recurrences represent reinfection hinders the assessment of risk factors for true relapse \[[@CIS356C14]\].

Recent guidelines \[[@CIS356C15]\] outline strategies for treating recurrent CDI. However, if patients at high risk could be identified earlier, relapse might be prevented by using novel therapies \[[@CIS356C1], [@CIS356C16]\]. Therefore, the objectives of this long-term population-based study were to identify independent predictors of CDI recurrence in Oxfordshire during 2006--2010 and to confirm which predictors were related to relapses caused by the same strain by using genotyping.

METHODS {#s2}
=======

Oxford Radcliffe Hospitals (ORH) NHS Trust provides \>90% of hospital care in Oxfordshire (population, approximately 600 000) and all acute services. The ORH Microbiology Laboratory tests all stool samples from the county, including those from other healthcare facilities and general practitioners (primary care). From September 2006, all unformed stools (taking the shape of the container) positive by enzyme immunoassay (EIA) for *C. difficile* toxins A and B (Meridian Bioscience, Cincinnati, Ohio) and with sufficient sample remaining were routinely cultured. *Clostridium difficile* isolates were genotyped by multilocus sequence typing (MLST) \[[@CIS356C17]\], typing morphologically distinct colonies separately. Infection control policy required samples from any admitted patient with diarrhea (locally defined as ≥3 unformed stools within 24 hours) to be tested for *C. difficile* and vancomycin treatment to be initiated empirically, continuing for 14 days if CDI is confirmed. From May 2007, all unformed stool samples from patients aged ≥65 years were routinely tested for *C. difficile* according to UK Department of Health policy (a mandatory test, typically not meeting the previous diarrhea definition).

*Clostridium difficile* MLST data were anonymously linked to information for ORH hospital admissions and discharges from April 1997 and mortality from the Infections in Oxfordshire Research Database (IORD) \[[@CIS356C18]\]. Admissions to other smaller hospitals in the area (including a specialist orthopedic, a psychiatric, and several community hospitals) were not included, although samples taken at these locations were identifiable. The IORD has Research Ethics Committee and UK National Information Governance Board approval.

We included the first CDI for each adult (aged ≥18 years) from September 2006 through December 2010 (when \>99% of samples had been typed), if the patient had no previous CDI recorded since April 1997. Included cases therefore had ≥3 months of potential follow-up to the 1 April 2011 data cutoff. Neither symptom resolution nor antibiotic use is routinely recorded electronically and, therefore, was not available for analysis. Because (1) patients received 14 days of vancomycin treatment, (2) most symptoms resolve before 14 days in successfully treated patients, and (3) UK Department of Health guidance was not to retest patients with ongoing diarrhea (ie, without resolution) for 28 days, the primary outcome was time from first-ever CDI to the first new EIA-positive sample ≥14 days later. Analyses therefore were restricted to patients known to be alive 14 days after the first CDI. The cumulative incidence of recurrence over time was estimated using competing risks methods to account for death before recurrence. Flexible parametric models were used to estimate precisely how the unadjusted daily recurrence risk varied with time from first CDI \[[@CIS356C19]\]. Cause-specific proportional hazards (Cox) models were used to estimate effects of factors theoretically available at treatment initiation (demographic characteristics, sample characteristics, previous ORH hospital exposure, and previous healthcare-associated infections; details in Table [1](#CIS356TB1){ref-type="table"}) on recurrence risk. Independent predictors were identified using backward selection with the Akaike information criterion \[[@CIS356C20]\], including pairwise interactions and allowing nonlinear effects of continuous factors through fractional polynomials. Categorical effects are presented for factors with significant evidence of nonlinearity. Results from regression models for the cumulative incidence subhazard for recurrence \[[@CIS356C21]\] (rather than the cause-specific hazard) were similar (data not shown). In all analyses, patients not known to have died were censored at their last hospital or laboratory contact. Table 1.Characteristics of First *Clostridium difficile* Infection, September 2006--December 2010Levels (for Continuous Factors, Unit Increase Corresponding to the RR in the Regression Model)No. (%) or Median (IQR)Unadjusted Univariable Cause-Specific Hazard ModelFactorOverallWith RecurrenceRR95% CIGlobal *P* ValueCDI, No. (%)1678 (100)393 (22)Demographics Sex, No. (%)Male711 (42)146 (21)1.00.36Female967 (58)217 (22)1.10.90--1.36 Age (y)(/10-y older)77 (64--85)79 (71--86)1.231.14--1.32\<.0001Previous hospital exposure Ever previously admitted to ORH, No. (%)^a^No230 (14)34 (15)1.00.11Yes, \<8-h admissions only108 (6)22 (20)1.13.74--1.75Yes, ≥1 admission for \>8 h1340 (80)307 (23)1.451.02--2.07 Last ORH admission, No. (%)\>1 y ago/never568 (34)103 (18)1.00.01Within the last y1110 (66)260 (23)1.331.06--1.67 Previous dialysis/ chemotherapy at ORH, No. (%)No1486 (89)323 (22)1.00.97Yes192 (11)40 (21)1.01.73--1.40 Previously admitted to ORH GI ward, No. (%)No1090 (65)241 (22)1.00.33Yes588 (35)122 (21)0.90.72--1.12 No. of previous admissions \>8 h(/5 additional \>8-h admissions)2 (1--5)3 (1--5)1.18^b^1.03--1.36.02 Total previous h in hospital (ORH) in admissions \>8 h (h)(/doubling of total previous h in hospital)366 (44--909)528 (122--1180)1.16^b^1.09--1.24\<.0001 Days since last discharged(/additional 6 mo since last ORH discharge)96 (23--870)77 (22--472)0.96.90--1.01.14 Discharged in last 7 d, No. (%)No1567 (93)331 (21)1.00.07Yes111 (7)32 (29)1.41.98--2.02 Likely source of first infection (IDSA/SHEA), No. (%) \[[@CIS356C15]\]Hospital onset, healthcare-associated880 (52)185 (21)1.00\<.001Community onset, healthcare-associated334 (20)80 (24)1.07.82--1.39Indeterminate127 (8)45 (35)1.771.27--2.45Community-associated337 (20)53 (16)0.64.47--.86 Previous MRSA, No. (%)No1503 (90)312 (21)1.00.01Yes175 (10)51 (29)1.45^c^1.08--1.95Sample characteristics Season, No. (%)Winter (Dec/Jan/Feb)424 (25)81 (19)1.00.35Spring (Mar/Apr/May)388 (23)86 (22)1.18.87--1.60Summer (Jun/Jul/Aug)431 (26)98 (23)1.31.97--1.76Autumn (Sep/Oct/Nov)435 (26)98 (23)1.20.89--1.61 Calendar year(/additional y)2008 (2007--2009)2008 (2007--2009)0.93.85--1.02.11 Mandatory EIA test (mild diarrhea), No. (%)No (requested by clinician)1404 (84)316 (23)1.00.01Yes (not requested)274 (16)47 (17)0.68.50--.92 Previous negative EIA testEver714 (43)187 (26)1.491.21--1.83Never964 (57)176 (18)1.00\<.0001 Previous negative EIA testIn last 14 d452 (27)261 (21)1.11.88--1.40Not in last 14 d1226 (73)102 (23)1.00.37 Location where first sample takenInpatient (overnight)1191 (71)260 (21)1.00.58Primary care294 (18)63 (22)0.83.63--1.09Outpatient/ED/day case87 (5)20 (23)0.91.58--1.44Other hospital106 (6)20 (19)0.88.56--1.39 If inpatient at first CDI, admission specialtySurgical376 (32)65 (17)1.00.03Medical815 (68)195 (24)1.371.11--1.68 If inpatient at first CDI, method of admissionElective237 (20)34 (14)1.00\<.0001Emergency954 (80)226 (24)1.581.10--2.27 If inpatient at first CDI, d since admittedWithin 2 d of admission311 (26)75 (24)1.00.50\>2 d after admission880 (74)185 (21)1.10.84--1.43 If inpatient at first CDI, d since admittedNonlinear effect^d^8 (2--20)10 (2--22) On d of admission128 (11)35 (27)1.51^d^.99--2.30 1--5 d after admission351 (29)67 (19)1.03^d^.72--1.47 6--14 d after admission311 (26)56 (18)1.00.03 ≥15 d after admission401 (34)102 (25)1.46^d^1.06--2.03Biomarkers^e^ C-reactive protein (mg/L)(/120 mg/L)^f^84 (33--156)97 (44--\>160)1.691.31--2.18\<.0001 White blood cell count (×10^9^/L)(/10 × 10^9^/L)^f^11.2 (7.8--16.1)12.2 (7.9--18.3)1.341.15--1.36\<.0001 Neutrophils (×10^9^/L)(/10 × 10^9^/L)^f^8.9 (5.6--13.4)9.7 (5.7--15.4)1.421.20--1.69\<.0001 Lymphocytes (×10^9^/L)(/10 × 10^9^/L)^f^11.0 (7.0--16.0)10.0 (7.0--15.0)0.84.73--.97.02 Albumin (g/L)(/10 g/L)34 (30--38)34 (30--37)0.82.68--1.00.05 Urea (mmol/L)(/5 mmol/L)^f^6.7 (4.5--11.0)7.3 (5.1--12.1)1.091.01--1.17.02[^1][^2][^3][^4][^5][^6][^7]

Baseline biomarker values were defined as the closest measurement within (−3, +1) days of the stool sample. Fourteen biomarkers available for \>50% of CDI cases were considered (white blood cell count, neutrophil count, lymphocyte count, C-reactive protein level, hemoglobin level, platelet count, and sodium, potassium, creatinine, urea, albumin, alanine aminotransferase, alkaline phosphatase, and bilirubin levels). To avoid bias and/or loss of power from restricting to complete cases with all biomarkers measured, associations between biomarkers and recurrence were estimated, imputing missing values in the subset of patients with at least 1 observed baseline biomarker. As recommended, chained estimating equations \[[@CIS356C22], [@CIS356C23]\] were used to create 20 imputations on BoxCox transformed variables \[[@CIS356C24]\], including all cofactors listed in Table [1](#CIS356TB1){ref-type="table"}, allowing nonlinearity in all continuous factors with natural cubic splines (knots at 10th, 50th, and 90th percentiles \[[@CIS356C25]\]) and including log(recurrence time) and the censoring indicator. Standard errors were estimated across imputations using Rubin\'s rules.

Stata software, version 11.2 (StataCorp, College Station, Texas), was used for all analyses, which were conducted by one of the authors (A. S. W.).

RESULTS {#s3}
=======

From September 2006 through December 2010, a total of 2043 adults had their first CDI (toxin EIA-positive stool sample with no previous positive). A total of 271 (13%) patients died within 0--13 days after the EIA-positive sample, and 94 (5%) had no follow-up after 13 days, leaving 1678 (82%) alive 14 days after the first CDI for analysis of recurrence.

Recurrence Rates {#s3a}
----------------

Overall, 363 of 1678 (22%) patients experienced a recurrence (new EIA-positive sample) ≥14 days after their first CDI, and 594 (35%) died without recurrence through March 2011. Median follow-up in those without recurrence was 11 months (interquartile range \[IQR\], 2--28 months). Cumulative incidences of recurrence increased to 7% and 16% by 1 and 2 months later, respectively (Figure [1](#CIS356F1){ref-type="fig"}*A*), corresponding to rates of 7.4 cases per 100 person-months at risk and 11.3 cases per 100 person-months at risk, respectively. Thereafter, the incidence increased more slowly to 18% and 20% by 3 and 4 months and to 22% and 23% at 1 and 2 years, respectively. The risk for recurrence was greatest 24 days after the first CDI, 10 days after cessation of treatment (Figure [1](#CIS356F1){ref-type="fig"}*B*). Of the 363 recurrences, 94 patients (26%) experienced a third CDI episode (≥14 days after the recurrence), of whom 24 had further episodes (maximum, 6) through March 2011. Figure 1.Time to recurrence. *A*, Months to new enzyme immunoassay (EIA)--positive sample or death ≥14 days after first-ever EIA-positive sample. *B*, Daily risk of post--14-day new EIA-positive sample. Abbreviations: AIC, Akaike information criterion; EIA, enzyme immunoassay.

Risk Factors for Recurrence {#s3b}
---------------------------

As expected, the population was predominantly older (median age, 77 years), although 302 (18%) were \<60 years of age at first CDI (Table [1](#CIS356TB1){ref-type="table"}). A total of 1191 (71%) were inpatients (admitted a median of 8 \[IQR, 2--20\] days), and most (1448; 86%) had previously been admitted to ORH facilities (66% in the past year). In a multivariable model (Table [2](#CIS356TB2){ref-type="table"}), recurrence risk independently was significantly higher among patients admitted as emergencies, those with previous gastroenterology ward admission(s), and after diagnosis on day of admission or ≥15 days after admission and also increased with age and increasing previous total hours in the hospital (all *P* \< .05). Risks also were higher among those for whom the last inpatient stay was 4--12 weeks before diagnosis (*P* = .006). Recurrence risk was independently lower among those with CDI diagnosed using a test that had not been clinically requested (a mandatory test, often for mild diarrhea; *P* = .07). Patients without previous hospital admissions generally had fewer other risk factors, but after adjusting for these, they had higher recurrence risks. One potential explanation, not assessable in our data, would be if such patients were more likely to be tertiary referrals with other non-ORH hospital exposure. Other factors (in particular, medical specialty, previous EIA-negative test result, number of previous admissions, and discharged in the previous 7 days) were significant in only univariable and not multivariable models (ie, were confounded with other factors). Table 2.Predictors of Recurrence ≥14 Days After First *Clostridium difficile* InfectionAll Recurrences Multivariable Cause-Specific Hazard Model^a^Shared STs Multivariable Cause-Specific Hazard Model^a^FactorLevels (Effect in Regression Model)RR95% CIGlobal *P* ValueRR95% CIGlobal *P* ValueNo. of CDI recurrences363169Age (y)(/10-y older)1.16\
1.57 (if previous dialysis/chemotherapy \[interaction *P* = .02\])1.07 -- 1.26\
1.23 -- 2.00.0004\
.00031.29\
1.71 (if previous dialysis/chemotherapy)1.13 -- 1.48\
1.19 -- 2.47.0001\
.004Total previous h in hospital (ORH) in admissions \>8 h (h)(/doubling of total previous h in hospital)1.29\
1.12 (if emergency admission \[interaction *P* = .002\])\
1.15 (if previous GI admission \[interaction *P* = .007\])1.17 -- 1.42\
1.03 -- 1.22\
\
1.04 -- 1.28\<.0001\
.008\
\
.0081.38\
1.15 (if emergency admission)\
1.24 (if previous GI admission)1.19 -- 1.60\
1.01 -- 1.30\
\
1.05 -- 1.46\<.0001\
.03\
\
.009Ever previously admitted to ORHNo or \<8-h admissions (vs yes for \>8-h admission)1.991.20 -- 3.31.0082.571.18 -- 5.62.02Mandatory EIA test (mild diarrhea)Yes (vs no)0.74.53 -- 1.03.070.67.41 -- 1.09.11If inpatient at first CDI, admission methodElective emergency1.00\
2.79\
5.10 (if previous MRSA \[interaction *P* = .0003\])\
4.74 (if previous dialysis/chemotherapy \[interaction *P* = .04\])\
1.29 -- 6.04\
2.12 -- 12.2\
\
1.96 -- 11.4\
.006\
.0003\
\
.00051.00\
4.85\
9.52\
\
8.79 (if previous dialysis/chemotherapy)\
1.42 -- 16.6\
2.42 -- 37.5\
\
2.23 -- 34.6\
.01\
.001\
\
.002Previous MRSAYes (vs no)0.45 (if not emergency).23 -- .88.020.70 (if not emergency).31 -- 1.59.39Previous dialysis/chemotherapy at ORHYes (vs no)0.77^a^ (if not emergency).39 -- 1.52.451.15^a^ (if not emergency).46 -- 2.82.77Previously admitted to ORH GI wardYes (vs no)2.331.13 -- 4.78.022.10.71 -- 6.23.18If inpatient at first CDI, d since admittedOn d of admission1.73^b^.52 -- 5.731.15.21 -- 6.311 -- 5 d after admission0.50^b^.21 -- 1.190.54.18 -- 1.656 -- 14 d after admission1.00.0061.00.38≥15 d after admission1.84^b^1.05 -- 3.231.37.62 -- 3.04If inpatient at first CDI, admission specialtyMedical (vs surgical)0.98^b^.34 -- 2.79.970.90.80 -- 1.01.08Location where first CDI sample takenNot inpatient (vs inpatient overnight)0.58^c^.20 -- 1.73.330.50.11 -- 2.39.39Likely source of first infection (IDSA/SHEA) \[15\]Hospital onset, healthcare-associated1.00.0061.00.07Community onset, healthcare-associated1.19.71 -- 2.001.71.77 -- 3.79Indeterminate2.031.16 -- 3.572.891.24 -- 6.76Community-associated1.03.60 -- 1.781.72.76 -- 3.89[^8][^9][^10][^11][^12]

In this multivariable model, 5 major effect modifications (interactions) were identified (Table [2](#CIS356TB2){ref-type="table"}): (1) increased risk at older ages was augmented in those with previous dialysis/chemotherapy, (2) increased risks associated with emergency admissions were augmented in those with previous methicillin-resistant *Staphylococcus aureus* (MRSA) infection or dialysis/chemotherapy, (3) recurrence risk increased less strongly with increasing previous total hours in the hospital in those admitted as emergencies and/or with previous gastroenterology ward admissions, (4) risk was significantly lower in those with previous MRSA infection and CDI in an elective admission (mostly surgical specialties; such patients received vancomycin and gentamicin perioperatively in place of broad-spectrum penicillin-based prophylaxis), and (5) recurrence risks varied less over days from admission to the first CDI diagnosis in medical than in nonmedical inpatients. No other factor listed in Table [1](#CIS356TB1){ref-type="table"} had an additional effect in this multivariable model (*P* \> .2). There also was no evidence of a trend over calendar year (*P* = .37) or season (*P* = .24).

The multivariable model in Table [2](#CIS356TB2){ref-type="table"} included factors theoretically available to clinicians at treatment initiation. Of importance, after adjusting for these, higher EIA optical density of the first *C. difficile* test was associated with a higher risk for recurrence, comparing across absolute values (relative risk \[RR\], 1.20 per unit higher \[95% confidence interval {CI}, 1.06--1.35\]; *P* = .003; median, 1.6 \[IQR, 0.5--\>2.5\]) or comparing the 37% with optical density exceeding the assay maximum (2.5) with other cases (RR, 1.33; 95% CI, 1.08--1.65; *P *= .008).

Biomarkers {#s3c}
----------

One or more of the 14 potential biomarkers was available in 1295 patients (77%), imputing missing data in this subgroup. Only higher C-reactive protein level and higher neutrophil count at first CDI independently increased recurrence risk, but the effect was much larger for C-reactive protein level (RR, 1.45 per 120 mg/L \[the IQR\] higher \[95% CI, 1.09--1.93\]; *P* = .01) than for neutrophil count (RR, 1.19 per 10 × 10^9^/L higher \[95% CI, .97--1.45\]; *P *= .09). Effects of other factors listed in Table [2](#CIS356TB2){ref-type="table"} were similar after adjusting for these baseline biomarkers.

Strain-Specific Recurrence Risks {#s3d}
--------------------------------

MLST was obtained for 1076 of 1678 (64%) first CDI cases: 418 (25%) samples did not yield *C. difficile* on culture (EIA-positive culture-negative samples), and 184 (11%) were not available for culture (28% pre-- vs 4% post--September 2007 when staff cover increased). A total of 685 (64%) typed isolates belonged to phylogenetic clade 1, from 56 STs, including those corresponding to PCR ribotypes 001, 002, 005, 014, 015, 020, 072, and 106 \[[@CIS356C26]\]. A total of 300 typed isolates (28%) belonged to clade 2 (295 of 300 PCR ribotype 027/ST1), and the remaining 91 (8%) belonged to clades 3, 4, and 5 ([Supplementary Table 1](http://cid.oxfordjournals.org/lookup/suppl/doi:10.1093/cid/cis356/-/DC1)). The crude percentages with recurrence were slightly higher after initial clade 2 CDI (90 of 300; 30%), compared with clade 1 (174 of 685; 25%; χ^2^ *P* = .13). After adjusting for risk factors listed in Table [2](#CIS356TB2){ref-type="table"}, recurrence risk appeared to be slightly higher after clade 2, compared with 1 CDI (RR, 1.17; 95% CI, .90--1.51; *P* = .24), but was compatible with chance. Recurrence risk was significantly lower for EIA-positive culture-negative samples (RR \[vs clade 1\], 0.41 \[95% CI, .29--.58\]; *P* \< .0001), supporting previous observations that this latter group likely represents false EIA-positive results \[[@CIS356C27], [@CIS356C28]\].

Relapse Versus Reinfection {#s3e}
--------------------------

Of the 363 recurrences after the first CDI, 219 (60%) had STs determined from both episodes. Making comparisons on the basis of individual STs, not clade, 169 (77%) recurrences had the same ST as the initial episode and 50 (23%) had no STs in common (ie, were new infections). The risk for same-ST recurrence was highest 14 days after first EIA-positive sample (Figure [2](#CIS356F2){ref-type="fig"}), then declined slowly during the next 2--6 months. In contrast, the risk for new ST infections peaked 30 days after the first CDI and then decreased sharply; recurrence risk among the 41 patients (11%) with EIA-positive culture-negative first CDI followed a similar pattern. For the other 103 recurrences (28%; STs not determined for ≥1 isolate), risk was a mixture distribution (data not shown). Figure 2.Time to recurrence ≥14 days after first *Clostridium difficile* infection according to shared or not shared sequence types. *A*, Months to new enzyme immunoassay (EIA)--positive sample ≥14 days after first-ever EIA-positive sample. *B*, Daily risk of new post--14-day EIA-positive sample. Abbreviations: CID, *Clostridium difficile* infection; EIA, enzyme immunoassay; ST, sequence type.

Predictors of the 169 recurrences with shared STs were very similar to predictors of all 363 recurrences (Table [2](#CIS356TB2){ref-type="table"}); with relatively small numbers, power was too low to conduct separate model selection. As expected, several factors appeared to have weaker effects on the 50 recurrences with no shared STs (presumed reinfections; data not shown).

Risk Score for Recurrence Following First CDI {#s3f}
---------------------------------------------

Because predictors of all CDI recurrences were similar to those for shared ST recurrences, we constructed an integer risk score (Table [3](#CIS356TB3){ref-type="table"}) based on the multivariable model for all recurrences (Table [2](#CIS356TB2){ref-type="table"}). The maximum possible score is 15 and minimum is −2; values of 0--13 were observed in our data set, with a median of 5 (IQR, 3--6). Models including the single risk score as a predictor provided an overall fit similar to the full Table [2](#CIS356TB2){ref-type="table"} model. Four-month recurrence risk was 6%--48% across the score (Figure [3](#CIS356F3){ref-type="fig"}); the absolute risk of recurrence 4 months after the first CDI increased by approximately 5% for every 1-point increase in score. Table 3.Score to Predict *Clostridium difficile* Infection (CDI) Recurrence Following First-Ever CDI DiagnosisFactorScoring CriteriaMaxMinPatient & health statusAge (y)60--6970--79≥80Score12330Emergency admissionAny emergency admission1AND previous MRSA+1AND/OR previous dialysis/chemotherapy130Severity of initial diseaseStool frequency≥3 unformed stools/d^a^1Admission with CDISample taken on day of inpatient admission1C-reactive protein^b^ (mg/L)\<3585--\<160≥160Score−1124−1Past health care exposureType of past admissionPast gastroenterology admissionNo past gastroenterology admissionTotal inpatient duration\
 before admissionAny past admission\>2--13 wk\>13 wkScore12330Antibiotic selection(Elective admission OR community sample) AND previous MRSA isolated^c^−10−1Susceptibility to diarrhea several wk after hospital exposurePrimary CDI 4--12 wk after hospital discharge^d^Community sample or sample taken within ≤2 d of inpatient admission AND patient discharged from hospital 4--12 wk previously220Total15−2[^13][^14][^15][^16][^17] Figure 3.Time to recurrence ≥14 days after first *Clostridium difficile* infection according to risk score. Abbreviation: EIA, enzyme immunoassay.

DISCUSSION {#s4}
==========

In our cohort of nearly 1700 patients surviving 2 weeks after their first CDI, 22% developed a symptomatic CDI recurrence during the 4-year study period. This is similar to commonly cited recurrence rates of approximately 20% \[[@CIS356C2]\] despite our considerably longer follow-up and robust design accounting for mortality. Most recurrences occurred within 2 months, but 4% of patients had recurrences at 2--4 months. The decrease in recurrence over time may reflect the eventual success of multiple treatment cycles \[[@CIS356C1], [@CIS356C9]\] or recovery from underlying illness with consequent lower exposure to antibiotics and restoration of more normal bowel flora able to suppress *C. difficile* growth in the colon \[[@CIS356C29]\]. Structural changes in bowel flora with age may impair such recovery \[[@CIS356C30]\]. Alternatively, because recurrence is associated with inadequate immune responses \[[@CIS356C31], [@CIS356C32]\], repeated relapse eventually may generate effective immunity, for example, to all phase variants of the cell surface--expressed proteins \[[@CIS356C33]\].

Two possible explanations exist for symptomatic recurrence: relapse of the same infection and reinfection. These can be distinguished, at least partially, by using strain typing data. In our study, 23% of recurrences were reinfection with a different strain, similar to the 26% reported in \[[@CIS356C14]\], but lower than the approximately 50% found by others \[[@CIS356C10]--[@CIS356C13]\]. Relapse may be more common in our cohort because of older age, compared with some other studies \[[@CIS356C11], [@CIS356C13]\]. Implementation of rigorous infection control measures \[[@CIS356C34]\] may also have reduced the incidence of reinfection. Of interest, reinfection with a different ST occurred most frequently 1 month after the first CDI (2--3 weeks after treatment cessation), possibly representing reexposure to *C. difficile* after clearance of the initial infection, whereas risks for new CDI with the same ST were greatest 14 days after the first CDI. Similar trends have been seen in other smaller studies \[[@CIS356C10], [@CIS356C11]\]. The relatively high prevalence of ST1/027/NAP-1, in 18% of cases, illustrates the difficulty distinguishing reinfection and relapse using genotyping schemes, such as MLST or ribotyping, with limited discriminatory power; the number of reinfections thus may be underestimated \[[@CIS356C15]\]. In the future, whole-genome sequencing may distinguish same-ST relapses from reinfections with different variants of common STs. Such distinctions are complicated further by the possibility of mixed initial or subsequent CDI; this was rarely identified in our cohort \[[@CIS356C35]\].

Our proposed score (Table [3](#CIS356TB3){ref-type="table"}) provides a summary of important risk factors for recurrence that would be present in electronic patient record systems. Several markers of underlying health status were either risk factors themselves or augmented the effect of other risk factors in our large unselected contemporaneous population, including increasing age, emergency admission, previous MRSA infection or colonization, and previous dialysis or chemotherapy. An initial CDI severe enough to be the probable cause of admission, to merit testing on the basis of clinical suspicion, or to increase levels of inflammatory markers, in particular, C-reactive protein, increased recurrence risk. We also found smaller risk increases with higher EIA optical density of the first CDI, which may reflect initial bacterial burden and/or toxin production \[[@CIS356C36]\]. Increasing past hospital exposure or gastrointestinal ward admission before the first CDI was also associated with recurrence. The increased recurrence risk after gastrointestinal admission requires confirmation in additional studies but may reflect increased CDI risk associated with inflammatory bowel disease \[[@CIS356C37], [@CIS356C38]\], nasogastric tube placement, possibly gastrointestinal endoscopy \[[@CIS356C39]\], and gastrointestinal surgery \[[@CIS356C40]\]. The apparent protective effect against CDI recurrence of previous MRSA infection or colonization on elective admissions is likely to reflect differences in the perioperative (and other) antibiotics received by this group, in particular, the replacement of broad-spectrum β-lactam antibiotics with glycopeptides and aminoglycosides. Conversely, previous MRSA was associated with higher recurrence risk in emergency admissions, possibly reflecting greater comorbidity in this group of patients who were also likely to receive broad-spectrum β-lactams in addition to glycopeptides. Initial CDI occurring 4--12 weeks after hospital discharge was also independently associated with recurrence. The delay in onset of the initial CDI in such cases may reflect prolonged susceptibility to the effects of hospital exposure (eg, mediated through failure of the immune system or change in bowel flora that also subsequently increases recurrence risk). Previously proposed scores for recurrence risk have been developed on much smaller hospital populations and have incorporated clinician opinion \[[@CIS356C5]\]. Nevertheless, further work to validate the score proposed here is essential. Of note, our risk score was constructed to capitalize on the types of data available in electronic patient records; we envisage that it could, for example, be incorporated into routine reports of positive CDI test results (if validated). This goal contrasts with other approaches to risk scoring for recurrence \[[@CIS356C5]\] and severity \[[@CIS356C41]\], which have been designed for use by clinicians at the bedside and often include assessments, such as temperature and endoscopy results not available in our study.

We did not find statistical evidence to support higher recurrence risk in clade 2 strains (almost exclusively ST1/027/NAP1), although we had low power (\<40%) to detect a significant difference in recurrence rates of 25% and 30% (as observed). More than 3 times as many cases would be needed to detect such a difference with 80% power, although it might still be clinically important, because every symptomatic recurrence reflects an additional opportunity for *C. difficile* transmission. However, it also is clear that CDI virulence remains poorly understood, with the variable virulence of PCR ribotype 027 strains demonstrated in vivo \[[@CIS356C42]\] and in vitro \[[@CIS356C43], [@CIS356C44]\], suggesting that factors at levels other than strain type may play a role.

Study limitations include the lack of prescribing data, meaning that we could not directly assess the potentially important roles of antibiotics and proton pump inhibitors \[[@CIS356C3], [@CIS356C45]\]. The limited sensitivity/specificity of EIA testing \[[@CIS356C28]\] also has implications for assessing recurrence; the reduced recurrence rate after EIA-positive culture-negative initial test results (Figure [2](#CIS356F2){ref-type="fig"}) supports that these do not represent true CDI. Several factors included in our risk score may not translate to other healthcare systems and practices, particularly diarrhea severity. Investigating whether they are specific to our hospitals or reflect important underlying risk determinants is essential. Finally, the underlying electronic data sources do not capture resolution or onset of symptoms, and therefore, our assessment of recurrence is based on time since the initial diagnosis and samples that were actually submitted. A proportion of our recurrences therefore may be persistent diarrhea. However, we are unlikely to have missed new symptomatic episodes because fecal sampling was common (500--1400 EIAs/month; median, 960) with a low clinical threshold to investigate patients with diarrhea; only 7% of samples were EIA positive. This limitation also means that we are unable to distinguish between effects of previously resolved and ongoing episodes of MRSA infection/colonization or dialysis/chemotherapy in risk models.

In summary, recurrence after CDI is an important problem. Early recurrence frequently represents relapse of the same infection. Risk factors, including increasing age, severity of initial disease, and hospital exposure, can predict recurrence, in particular, relapse of the same infection, and may identify patients who would benefit from enhanced treatment of an initial CDI episode. Late recurrences highlight the ongoing need for interventions to prevent *C. difficile* transmission.
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[^1]: Abbreviations: CDI, *Clostridium difficile* infection; CI, confidence interval; ED, emergency department; EIA, enzyme immunoassay; GI, gastrointestinal; IDSA, Infectious Diseases Society of America; IQR, interquartile range; MRSA, methicillin-resistant *Staphylococcus aureus*; ORH, Oxford Radcliffe Hospitals; RR, relative risk; SHEA, Society for Healthcare Epidemiology of America.

[^2]: ^a^ Excluding current admission if inpatient.

[^3]: ^b^ Univariable model also adjusts for ever vs never previously admitted for \>8 h.

[^4]: ^c^ Approximate IQR.

[^5]: ^d^ Significant nonlinearity (*P* \< .0001; univariable model also adjusts for current inpatient), with greatest risk for death on day of admission, then decreasing sharply and then gradually increasing. Results presented for diagnoses made on day of admission, then approximate tertiles of days from admission to first diagnosis in inpatients.

[^6]: ^e^ Imputed in the subset of 1295 (77%) patients with at least 1 of the 14 potential biomarkers available (see Methods for details). Reference ranges: C-reactive protein, 0--8 mg/L; white blood cell count, 4 -- 11 × 10^9^/L (no reference range for neutrophils or lymphocytes, which are measured as a percentage of white blood cell count); albumin, 35 -- 50 g/L; urea, 2.5 -- 6.7 mmol/L. None of the biomarkers not shown had an effect in univariable models (*P* \> .1).

[^7]: ^f^ Significant interaction between previous MRSA and emergency/elective admission (Table [2](#CIS356TB2){ref-type="table"}), such that previous MRSA increases CDI recurrence risk for emergency admissions, but decreases CDI recurrence risk for elective admissions (such patients received vancomycin and gentamicin perioperatively in place of broad-spectrum penicillin-based prophylaxis).

[^8]: All other factors in Table [1](#CIS356TB1){ref-type="table"} had no additional effect on CDI recurrence (*P* \> .2). Results were similar when excluding 418 cases whose first *Clostridium difficile* infection was EIA positive and culture negative.

[^9]: Abbreviations: CDI, *Clostridium difficile* infection; CI, confidence interval; EIA, enzyme immunoassay; GI, gastrointestinal; IDSA, Infectious Diseases Society of America; MRSA, methicillin-resistant *Staphylococcus aureus*; ORH, Oxford Radcliffe Hospitals; RR, relative risk; SHEA, Society for Healthcare Epidemiology of America; ST, sequence type.

[^10]: ^a^ Effect of previous dialysis/chemotherapy estimated for a person aged 77 years; significant interaction with age (*P* = .03).

[^11]: ^b^ RR presented for admissions to nonmedical specialties: less variation in risk for patients admitted to medical specialties (mostly also emergency admissions), with RRs of 1.21 (95% CI, .60 -- 2.41), 0.96 (95% CI, .58 -- 1.61), 1.00, and 1.10 (95% CI, .73 -- 1.66) for first CDI diagnoses 0, 1 -- 5, 6 -- 14, and ≥15 days after admission, respectively (interaction *P* = .05).

[^12]: ^c^ First CDI during inpatient admission (yes vs no) included in final model to allow those not admitted to differ from those with first CDI on day of admission.

[^13]: Abbreviations: CDI, *Clostridium difficile* infection; Max, maximum; Min, minimum; MRSA, methicillin-resistant *Staphylococcus aureus*; MRSA+, MRSA positive.

[^14]: ^a^ "Mandatory" tests in our study taken to represent mild diarrhea with \<3 unformed stools per day.

[^15]: ^b^ Score 0 if C-reactive protein not measured or not available at first CDI.

[^16]: ^c^ Proxy for receiving vancomycin ± gentamicin rather than co-amoxiclav or other provocative antibiotics for surgical prophylaxis or other treatment.

[^17]: ^d^ Infectious Diseases Society of America/Society for Healthcare Epidemiology of America indeterminate \[[@CIS356C15]\].
